+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vaginitis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 75 Pages
  • October 2023
  • Region: Global
  • Grand View Research
  • ID: 5899525
Description Jump to:
The global vaginitis therapeutics market size is expected to reach USD 6.0 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

Vaginitis Therapeutics Market Report Highlights

  • Anti-bacterial segment led the market for vaginitis therapeutics with a revenue share of 37.9% in 2022 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
  • Hormone is expected to witness lucrative growth with a CAGR of 8.4% over the forecast period due to the presence of pipeline products and rising adoption of products
  • The prescription segment led the market with the largest revenue share of 51.2% in 2022, owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
  • Over the counter segment is expected to expand at a CAGR of 8.7% in the coming years due to increasing number of FDA approvals for the treatment of mild vaginitis
  • North America dominated the market with a revenue share of 38.3% in 2022, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
  • Asia Pacific is estimated to witness the fastest growth, with a CAGR of around 9.5% over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Disease Type
1.1.2. Product
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease Type outlook
2.2.2. Product outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Vaginitis Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Vaginitis Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Vaginitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Vaginitis Therapeutics Market: Disease Type Key Takeaways
4.2. Vaginitis Therapeutics Market: Disease Type Movement & Market Share Analysis, 2022 & 2030
4.3. Anti-fungal
4.3.1. Anti-fungal market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Anti-bacterial
4.4.1. Anti-bacterial market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Hormone
4.5.1. Hormone market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Vaginitis Therapeutics Market: Product Estimates & Trend Analysis
5.1. Vaginitis Therapeutics Market: Product Key Takeaways
5.2. Vaginitis Therapeutics Market: Product Movement & Market Share Analysis, 2022 & 2030
5.3. Over-the-counter
5.3.1. Over-the-counter market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Prescription
5.4.1. Prescription market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Vaginitis Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Vaginitis Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Symbiomix Therapeutics LLC.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Merck & Co., Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Pfizer Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Novartis AG
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Teva Pharmaceutical Industries Ltd.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bayer AG
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Janssen Pharmaceuticals Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Lupin Pharmaceuticals Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Lumavita AG
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Mission Pharmacal Company
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 3 North America vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 4 North America vaginitis therapeutics market, by region, 2018-2030 (USD Million)
Table 5 U.S. vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 6 U.S. vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 7 Canada vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 8 Canada vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 9 Europe vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 10 Europe vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 11 Europe vaginitis therapeutics market, by region, 2018-2030 (USD Million)
Table 12 Germany vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 13 Germany vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 14 UK vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 15 UK vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 16 France vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 17 France vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 18 Italy vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 19 Italy vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 20 Spain vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 21 Spain vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 22 Sweden vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 23 Sweden vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 24 Norway vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 25 Norway vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 26 Denmark vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 27 Denmark vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 28 Asia Pacific vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 29 Asia Pacific vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 30 Asia Pacific vaginitis therapeutics market, by region, 2018-2030 (USD Million)
Table 31 China vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 32 China vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 33 Japan vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 34 Japan vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 35 India vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 36 India vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 37 Australia vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 38 Australia vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 39 Thailand vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 40 Thailand vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 41 South Korea vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 42 South Korea vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 43 Latin America vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 44 Latin America vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 45 Latin America vaginitis therapeutics market, by region, 2018-2030 (USD Million)
Table 46 Brazil vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 47 Brazil vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 48 Mexico vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 49 Mexico vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 50 Argentina vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 51 Argentina vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 52 Middle East and Africa vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 53 Middle East and Africa vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 54 Middle East and Africa vaginitis therapeutics market, by region, 2018-2030 (USD Million)
Table 55 South Africa vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 56 South Africa vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 57 Saudi Arabia vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 58 Saudi Arabia vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 59 UAE vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 60 UAE vaginitis therapeutics market, by product, 2018-2030 (USD Million)
Table 61 Kuwait vaginitis therapeutics market, by disease type, 2018-2030 (USD Million)
Table 62 Kuwait vaginitis therapeutics market, by product, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Vaginitis Therapeutics: Market outlook
Fig. 9 Vaginitis Therapeutics: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Vaginitis Therapeutics market driver impact
Fig. 15 Vaginitis Therapeutics market restraint impact
Fig. 16 Vaginitis Therapeutics market strategic initiatives analysis
Fig. 17 Vaginitis Therapeutics market: Disease type movement analysis
Fig. 18 Vaginitis Therapeutics market: Disease type outlook and key takeaways
Fig. 19 Anti-fungal market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 20 Anti-bacterial market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 21 Hormone market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 22 Vaginitis Therapeutics market: Product movement analysis
Fig. 23 Vaginitis Therapeutics market: Product outlook and key takeaways
Fig. 24 Over-the-counter market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 25 Prescription (Rx) market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 26 Global Vaginitis Therapeutics market: Regional movement analysis
Fig. 27 Global Vaginitis Therapeutics market: Regional outlook and key takeaways
Fig. 28 North America market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 29 U.S. market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 30 Canada market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 31 Europe market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 32 UK market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 33 Germany market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 34 France market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 35 Italy market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 36 Spain market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 37 Sweden market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 38 Norway market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 39 Denmark market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 40 Asia Pacific market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 41 Japan market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 42 China market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 43 India market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 44 Australia market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 45 Thailand market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 46 South Korea market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 47 Latin America market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 48 Brazil market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 49 Mexico market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 50 Argentina market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 51 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 52 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 53 South Africa market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 54 UAE market estimates and forecasts, 2018-2030 (USD Billion)
Fig. 55 Kuwait market estimates and forecasts, 2018-2030 (USD Billion)

Companies Mentioned

  • Symbiomix Therapeutics LLC.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Janssen Pharmaceuticals Inc.
  • Lupin Pharmaceuticals Inc.
  • Lumavita AG
  • Mission Pharmacal Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages75
PublishedOctober 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 3.2 Billion
Forecasted Market Value ( USD ) by 2030 $ 6 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Vaginitis Therapeutics Market by Drug Type (Anti-bacterial, Anti-fungal, Hormone), Offering (Over-The-Counter (OTC), Prescription), Route of Administration, Distribution Channel - Forecast 2024-2030 - Product Image

Global Vaginitis Therapeutics Market by Drug Type (Anti-bacterial, Anti-fungal, Hormone), Offering (Over-The-Counter (OTC), Prescription), Route of Administration, Distribution Channel - Forecast 2024-2030

  • Report
  • 196 Pages
  • Global
From
Global Vaginitis Therapeutics Market Analysis & Forecast to 2024-2034 - Product Image

Global Vaginitis Therapeutics Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Vaginitis Therapeutics Global Market Report 2024 - Product Image

Vaginitis Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Vaginitis Therapeutics - Global Strategic Business Report - Product Image

Vaginitis Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Vaginitis Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Vaginitis Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 133 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.